GS
GSGTF.US GenSight Biologics S.A
- Market cap
- USD 19.6M
- P/E
- -
- P/B
- 41.46x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is GSGTF.US undervalued?
Graham numberThe Graham number of GenSight Biologics S.A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GenSight Biologics S.A fundamental analysis
No fundamental analysis for GenSight Biologics S.A yet.
GenSight Biologics S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GenSight Biologics S.A
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of…
Full company profileGenSight Biologics S.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GenSight Biologics S.A annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.00M | 3.70M | 4.35M | 700K | 4.39M | 5.28M | 2.58M | 1.27M | 1.50M | 999.63 | -3.42M |
| Gross Profit | 2.80M | 3.48M | 4.03M | 700K | 4.39M | 5.28M | 2.58M | 1.27M | 1.50M | 1.00K | -3.42M |
| Operating Income | -22.0M | -24.0M | -33.0M | -30.3M | -24.9M | -28.1M | -27.8M | -29.7M | -15.8M | -11.7M | -34.1M |
| EBITDA | -21.8M | -23.8M | -32.7M | -29.3M | -24.0M | -27.2M | -26.8M | -20.9M | -11.4M | -11.2M | -34.5M |
| Net Income | -22.1M | -24.1M | -33.5M | -30.7M | -34.0M | -28.6M | -27.6M | -26.2M | -14.0M | -12.0M | -40.8M |
| EPS | -1.36 | -1.10 | -1.37 | -1.08 | -0.97 | -0.63 | -0.60 | -0.54 | -0.17 | -0.08 | -0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 59.2M | 62.2M | 37.0M | 32.5M | 47.4M | 56.6M | 25.9M | 9.13M | 10.8M | 8.25M | 6.45M |
| Total Liabilities | 5.89M | 7.22M | 13.1M | 20.7M | 35.7M | 40.7M | 41.2M | 39.8M | 37.7M | 33.2M | 40.1M |
| Shareholders' Equity | 53.3M | 55.0M | 23.9M | 11.7M | 11.7M | 16.0M | -15.3M | -30.7M | -26.9M | -24.9M | -33.6M |
| Cash & Short-term Investments | 54.0M | 55.4M | 26.2M | 19.3M | 37.9M | 44.3M | 10.6M | 2.13M | 2.46M | 2.41M | 1.67M |
| Total Debt | 2.92M | 3.03M | 3.44M | 7.20M | 14.5M | 12.6M | 17.9M | 23.5M | 19.1M | 12.9M | 12.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -19.6M | -18.8M | -28.4M | -28.1M | -15.0M | -17.1M | -33.8M | -24.7M | -12.9M | -9.17M | -6.87M |
| Capital Expenditure | 189K | 236K | 791K | 76.0K | 6.00K | 32.0K | 252K | 10.0K | 1.00K | 9.17M | 262K |
| Free Cash Flow | -19.8M | -19.0M | -29.2M | -28.2M | -15.1M | -17.2M | -34.0M | -24.7M | -12.9M | -9.17M | -7.14M |
| Ratios | |||||||||||
| ROE | -41.4% | -43.8% | -140.1% | -261.5% | -289.5% | -179.0% | - | - | - | - | - |
| ROA | -37.3% | -38.8% | -90.5% | -94.5% | -71.8% | -50.5% | -106.5% | -287.1% | -130.2% | -145.8% | -632.2% |
| Net Profit Margin | -735.8% | -651.3% | -769.7% | -4,387.1% | -774.1% | -542.4% | -1,069.9% | -2,069.5% | -933.4% | -1,203,594.4% | - |
| Debt to Equity | 0.05x | 0.06x | 0.14x | 0.61x | 1.23x | 0.79x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GenSight Biologics S.A dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 6.37M | 0.14 | - |
| 2021 | USD 359K | 0.01 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns GenSight Biologics S.A
- Insiders 6.75%
- Institutions 39.32%
- Public & others 53.93%
- Shares outstanding 245M
- Free float 136M
GenSight Biologics S.A company profile
- Company name
- GenSight Biologics S.A
- Ticker
- GSGTF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 18
- Fiscal year end
- December
- Address
- 74, rue du Faubourg Saint-Antoine, Paris, France, 75012
- Phone
- 33 1 76 21 72 20
- Website
- gensight-biologics.com
About GenSight Biologics S.A
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa and dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.
GenSight Biologics S.A management
10- Ms. Laurence RodriguezCEO & Director · born 1968
- Dr. Jose-Alain Sahel M.D., Ph.D.Scientific Founder, Vice Chairman of Scientific Advisory Board & Director · born 1956
- Dr. Botond Roska M.D., Ph.D.Scientific Founder & Chairman of Scientific Advisory Board
- Dr. Serge Picaud Ph.D.Scientific Founder & Member of Scientific Advisory Board
- Mr. Jan Eryk UmiastowskiChief Financial Officer
- Mr. Julio BenedictoSenior Vice President of Strategy & Operations
- Mr. Scott JeffersChief Technical Officer
- Dr. Barrett Katz CMO, M.B.A., M.D.Consultant · born 1951
- Dr. Magali Taiël M.D.Chief Medical Officer
- Dr. Fang Li Ph.D.Chief Regulatory & Quality Officer · born 1965